What question did this study set out to answer?

To evaluate the long-term survival outcomes and safety of dostarlimab in patients with dMMR/MSI-H endometrial cancer after platinum-based chemotherapy.

July 4, 2026Open Access

69O Six-year survival outcomes with dostarlimab monotherapy in patients (pts) with mismatch repair-deficient/microsatellite-high (dMMR/MSI-H) endometrial cancer (EC) in the GARNET trial

Key Points

To evaluate the long-term survival outcomes and safety of dostarlimab in patients with dMMR/MSI-H endometrial cancer after platinum-based chemotherapy.
Conducted as part of the GARNET trial focusing on patients with advanced/recurrent endometrial cancer.
Updated efficacy and safety data were gathered at a six-year follow-up and included a conditional survival analysis.
Demonstrated durable antitumor activity with dostarlimab, indicating sustained benefits over six years.
Showed acceptable safety profiles consistent with previous findings, emphasizing its viability as a treatment option.

Abstract

The GARNET trial is the largest trial of an anti-PD-1 monotherapy, dostarlimab, in patients with dMMR/MSI-H advanced/recurrent (A/R) EC after platinum-based chemotherapy and supported global approvals in this setting. Previously published results provided robust evidence of clinical benefit and demonstrated durable antitumor activity with an acceptable safety profile. Here we report updated efficacy and safety at 6y follow-up accompanied by a conditional survival analysis to provide prognostic insights into long-term survival potential.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper